← Leaderboards
Charles Read
Georgetown University
$268,400
Attributed
$268,400
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$268,400 · 2
By mechanism
U01$244,547 · 1
M01$23,853 · 1
Top collaborators
No co-investigators on record.
Most similar at Georgetown University
Same institution · by research overlap
- Donald J Massaro$6,637,249
- Virginia D Steen$175,236
- Gloria D Massaro$1,629,600
- Regina M Day$1,379,469
- Naiyer A Rizvi$2,808,393
Others in their field
Top investigators on “Systemic Scleroderma”
- Eugene W. St Clair · Duke University$24,182,181
- John Varga · University Of Illinois At Chicago$13,781,985
- Carol A Feghali-Bostwick · University Of Pittsburgh At Pittsburgh$11,771,501
- Judith A James · Oklahoma Medical Research Foundation$11,331,322
- Robert M Elashoff · John Wayne Cancer Institute$10,394,671
- Maria Trojanowska · Boston University Medical Campus$10,085,547
Research focus
Systemic SclerodermaDyspneasHuman SubjectHuman Therapy EvaluationInflammationPulmonary Fibrosis /GranulomaQuality Of LifeRespiratory Airway VolumeRespiratory Disorder ChemotherapyClinical ResearchCyclophosphamideDrug Screening /EvaluationLung AlveolusCooperative StudyFunctional AbilityDiagnostic Respiratory LavageLongitudinal Human StudyPatient Oriented ResearchRespiratory FunctionOral AdministrationClinical Trials
Grant awards (5)
Oral cyclophosphamide vs. oral placebo in systemic sclerosis pulmonary alveoliti$23,853
M01 · FY2004 · RR
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$1
U01 · FY2003 · HL
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$65,185
U01 · FY2002 · HL
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$94,634
U01 · FY2001 · HL
ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS$84,727
U01 · FY2000 · HL